# US 2024/0002908 A1 · Methods of determining surface glycan density

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002908 A1
- Document ID: US20240002908A1
- Status: Published application
- Kind: A1
- Application number: 18/036,008
- Filed: 2021-11-05
- Published: 2024-01-04
- Earliest claimed: 2020-11-09
- Applicants: The General Hospital Corporation
- Inventors: James T. Kurnick; Ian Seymour Dunn; Matthew M. Lawler
- Web page: https://patentgrep.com/patent/US20240002908A1

## CPC

- C12Q 1/6816: characterised by the detection means (C12Q1/6804 takes precedence)
- C12Q 2600/166: Oligonucleotides used as internal standards, controls or normalisation probes
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure provides methods of determining surface glycan density of a cell.

## Claims

### Claim 1

A method of determining surface glycan density of a cell, the method comprising the steps:
a) contacting the cell with an azide-modified sugar;
b) contacting the cell with a nucleic acid template comprising a 5′- or 3′-azide reactive molecule that is chemically reactable with an azide group, wherein the nucleic acid template has a first haplomer hybridization region and a second haplomer hybridization region;
c) contacting the cell with a first haplomer comprising:
i) a first oligonucleotide conjugated to a first ligand, wherein the first oligonucleotide is complementary to the first haplomer hybridization region; and
ii) a first fragment of a reporter molecule conjugated to a first ligand binding domain;
wherein the first ligand and first ligand binding domain associate with one another;
d) contacting the cell with a second haplomer comprising:
i) a second oligonucleotide conjugated to a second ligand, wherein the second oligonucleotide is complementary to the second haplomer hybridization region; and
ii) a second fragment of the reporter molecule conjugated to a second ligand binding domain;
wherein the second ligand and the second ligand binding domain associate with one another;
whereby, upon hybridization of the first oligonucleotide to the first haplomer hybridization region and the second oligonucleotide to the second haplomer hybridization region, and refolding of the first fragment of the reporter molecule with the second fragment of the reporter molecule, a functional reporter molecule is produced; and
e) detecting the amount of reporter molecule activity.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the azide reactive molecule is dibenzocyclooctyne (DBCO), bicyclo[6.1.0]nonyne (BCN), methyltetrazine, or trans-cyclooctene (TCO).

### Claim 3 (depends on 1, 2)

The method according to claim 1 or claim 2, wherein the azide-modified sugar is azido-N-acetylmannosamine (AzNAM), azido-N-acetylglucosamine (AzGlcNAc), azido-N-acetylgalactosamine (AGalNAc), or azido-N-acetylneuraminic acid (AzNANA).

### Claim 4 (depends on 1, 2, 3)

The method according to any one of claims 1 to 3, wherein the azide-modified sugar is acetylated at 1, 2, 3, or 4 positions.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1 to 4, wherein the nucleic acid template comprising the 5′- or 3′-azide reactive molecule is a mixture of two nucleic acid templates comprising the 5′- or 3′-azide reactive molecule, wherein the first nucleic acid template comprising the 5′- or 3′-azide reactive molecule is hybridized to a blocking oligonucleotide that is complementary to the first haplomer hybridization region, and wherein the second nucleic acid template comprising the 5′- or 3′-azide reactive molecule is hybridized to a blocking oligonucleotide that is complementary to the second haplomer hybridization region.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1 to 5, wherein the first ligand and second ligand are small molecule ligands.

### Claim 7 (depends on 6)

The method of claim 6, wherein the small molecule ligand is an FKBP-binding compound.

### Claim 8 (depends on 7)

The method of claim 7, wherein the FKBP-binding compound is chosen from FKM-NHS, FKM-sulfo-NHS, FKM-PEG3-NHS, monovalent FKBP Ligand-2 (MFL2), FKM-PEG3-MTZ-NHS, and FKM-PEG3-TCO-NHS.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1 to 8, wherein the first ligand binding domain and second ligand binding domains are FKBP domains or FRB domains.

### Claim 10 (depends on 9)

The method of claim 9, wherein the FKBP domain is a mutant FKBP domain.

### Claim 11 (depends on 10)

The method of claim 10, wherein the mutant FKBP domain is the F36V FKBP mutant domain comprising the amino acid sequence GVQVETISPGDGRTFPKRGQTCVVH YTGMLEDGKKVDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDY AYGATGHPGIIPPHATLVFDVELLKLE (SEQ ID NO: 1) or MGVQVETISPGDGRTFPKR GQTCVVHYTGMLEDGKKVDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRA KLTISPDYAYGATGHPGIIPPHATLVFDVELLKLE (SEQ ID NO:2).

### Claim 12 (depends on 10)

The method of claim 10, wherein the mutant FKBP domain comprises a C22S, C22A, or C22V substitution.

### Claim 13 (depends on 9)

The method of claim 9, wherein the FRB domain comprises a C61S, C61A, or C61V substitution.

### Claim 14 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1 to 5, wherein the first ligand and first ligand binding domain and/or the second ligand and second ligand binding domain are small interactive protein domain pairs.

### Claim 15 (depends on 14)

The method of claim 14, wherein the small interactive protein domain pairs are chosen from jun/fos, mad/max, myc/max, and NZ/CZ domains.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method according to any one of claims 1 to 15, wherein the reporter molecule is chosen from a luminescent protein, murine dihydrofolate reductase (DHFR), S. cerevisiae ubiquitin, β-lactamase, and Herpes simplex virus type 1 thymidine kinase.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the reporter molecule is DHFR, and one of the first fragment of the reporter molecule and the second fragment of the reporter molecule comprises amino acids 1-105 of DHFR, and the other of the first fragment of the reporter molecule and second fragment of the reporter molecule comprises amino acids 106-186 of DHFR.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the reporter molecule is S. cerevisiae ubiquitin, and one of the first fragment of the reporter molecule and the second fragment of the reporter molecule comprises amino acids 1-34 (MQIFVKTLTGKTITLEVESSDTIDNV KSKIQDKE; SEQ ID NO:3) of S. cerevisiae ubiquitin, and the other of the first fragment of the reporter molecule and second fragment of the reporter molecule comprises amino acids 35-76 (GIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG; SEQ ID NO:4) of S. cerevisiae ubiquitin.

### Claim 19 (depends on 16)

The method according to claim 16, wherein the reporter molecule is β-lactamase, and one of the first fragment of the reporter molecule and the second fragment of the reporter molecule comprises amino acids 25-197 of β-lactamase, and the other of the first fragment of the reporter molecule and second fragment of the reporter molecule comprises amino acids 198-286 of β-lactamase.

### Claim 20 (depends on 16)

The method according to claim 16, wherein the reporter molecule is Herpes simplex virus type 1 thymidine kinase, and one of the first fragment of the reporter molecule and the second fragment of the reporter molecule comprises amino acids 1-265 of Herpes simplex virus type 1 thymidine kinase, and the other of the first fragment of the reporter molecule and second fragment of the reporter molecule comprises amino acids 266-376 of Herpes simplex virus type 1 thymidine kinase.

### Claim 21 (depends on 16)

The method according to claim 16, wherein the luminescent protein is Gaussia luciferase, superfolder GFP (sfGFP), Renilla luciferase, or Nanoluc luciferase.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the luminescent protein is Gaussia luciferase, and one of the first fragment of Gaussia luciferase and second fragment of Gaussia luciferase comprises MKPTENNEDFNIVAVASNFATTDLDADRGKLPGKKLPLEVLKE MEANARKAGCTRGCLICLSHIKCTPKMKKFIPGRCHTYEGDKESAQGGIG (SEQ ID NO:5), and the other of the first fragment of Gaussia luciferase and second fragment of Gaussia luciferase comprises EAIVDIPEIPGFKDLEPMEQFIAQVDLCVDCTTGCLKGLA NVQCSDLLKKWLPQRCATFASKIQGQVDKIKGAGGD (SEQ ID NO:6).

### Claim 23 (depends on 21)

The method according to claim 21, wherein the luminescent protein is sfGFP, and one of the first fragment of sfGFP and second fragment of sfGFP comprises MRKGEELFT GVVPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGKLPVPWPTLVTTLTY GVQCFARYPDHMKQHDFFKSAMPEGYVQERTISFKDDGTYKTRAEVKFEGDTLVN RIELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQ (SEQ ID NO:7) or MSKGEELFT GVVPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGKLPVPWPTLVTTLTY GVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGTYKTRAEVKFEGDTLVNR IELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQ (SEQ ID NO:22), and the other of the first fragment of sfGFP and second fragment of sfGFP comprises KNGIKANFKIRHNV EDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLSKDPNEKRDHMVLLEFVTAA GITHGMDELYK (SEQ ID NO:8).

### Claim 24 (depends on 21)

The method according to claim 21, wherein the luminescent protein is Renilla luciferase, and one of the first fragment of Renilla luciferase and second fragment of Renilla luciferase comprises MASKVYDPEQRKRMITGPQWWARCKQMNVLDSFINYYDSEKH AENAVIFLHGNAASSYLWRHVVPHIEPVARCIIPDLIGMGKSGKSGNGSYRLLDHYK YLTAWFELLNLPKKIIFVGHDWGACLAFHYSYEHQDKIKAIVHAESVVDVIESWDE WPDIEEDIALIKSEEGEKMVLENNFFVETMLPSKIMRKLEPEEFAAYLEPFKEKGEVR RPTLSWPREIPLVKGG (SEQ ID NO:9), and the other of the first fragment of Renilla luciferase and second fragment of Renilla luciferase comprises KPDVVQIVRNYNAYLRAS DDLPKMFIESDPGFFSNAIVEGAKKFPNTEFVKVKGLHFSQEDAPDEMGKYIKSFVER VLKNEQ (SEQ ID NO:10).

### Claim 25 (depends on 21)

The method according to claim 21, wherein the luminescent protein is Nanoluc luciferase, and one of the first fragment of Nanoluc luciferase and second fragment of Nanoluc luciferase comprises MFTLEDFVGDWEQTAAYNLDQVLEQGGVSSLLQNLAV SVTPIQRIVRSGENALKIDIHVIIPYEGLSADQMAQIEEVFKVVYPVDDHHFKVILPYG TLVIDGVTPNMLNYFGRPYEGIAVFDGKKITVTGTLWNGNKIIDERLITPDGSMLFRV TINS (SEQ ID NO:34), and the other of the first fragment of Nanoluc luciferase and second fragment of Nanoluc luciferase comprises VSGWRLFKKIS (SEQ ID NO:35) or VTGYRL FEEIL (SEQ ID NO:36).

### Claim 26

A method of determining surface glycan density of a cell, the method comprising the steps:
a) contacting the cell with an azide-modified sugar;
b) contacting the cell with a first nucleic acid template comprising a 5′-azide reactive molecule that is chemically reactable with an azide group, wherein the nucleic acid template has a first haplomer hybridization region;
c) contacting the cell with a second nucleic acid template comprising a 3′-azide reactive molecule that is chemically reactable with an azide group, wherein the nucleic acid template has a second haplomer hybridization region;
d) contacting the cell with a first haplomer comprising:
i) a first oligonucleotide conjugated to a first ligand, wherein the first oligonucleotide is complementary to the first haplomer hybridization region; and
ii) a first fragment of a reporter molecule conjugated to a first ligand binding domain;
wherein the first ligand and the first ligand binding domain associate with one another;
e) contacting the cell with a second haplomer comprising:
i) a second oligonucleotide conjugated to a second ligand, wherein the second oligonucleotide is complementary to the second haplomer hybridization region; and
ii) a second fragment of the reporter molecule conjugated to a second ligand binding domain;
wherein the second ligand and the second ligand binding domain associate with one another;
whereby, upon hybridization of the first oligonucleotide to the first haplomer hybridization region and the second oligonucleotide to the second haplomer hybridization region, and refolding of the first fragment of the reporter molecule with the second fragment of the reporter molecule, a functional reporter molecule is produced; and
f) detecting the amount of reporter molecule activity.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the azide reactive molecule is dibenzocyclooctyne (DBCO), bicyclo[6.1.0]nonyne (BCN), methyltetrazine, or trans-cyclooctene (TCO).

### Claim 28 (depends on 26, 27)

The method according to claim 26 or claim 27, wherein the azide-modified sugar is azido-N-acetylmannosamine (AzNAM), azido-N-acetylglucosamine (AzGlcNAc), azido-N-acetylgalactosamine (AGalNAc), or azido-N-acetylneuraminic acid (AzNANA).

### Claim 29 (depends on 26, 27, 28)

The method according to any one of claims 26 to 28, wherein the azide-modified sugar is acetylated at 1, 2, 3, or 4 positions.

### Claim 30 (depends on 26, 27, 28, 29)

The method of any one of claims 26 to 29, wherein the first ligand and second ligand are small molecule ligands.

### Claim 31 (depends on 30)

The method of claim 30, wherein the small molecule ligand is an FKBP-binding compound.

### Claim 32 (depends on 31)

The method of claim 31, wherein the FKBP-binding compound is chosen from FKM-NHS, FKM-sulfo-NHS, FKM-PEG3-NHS, monovalent FKBP Ligand-2 (MFL2), FKM-PEG3-MTZ-NHS, and FKM-PEG3-TCO-NHS.

### Claim 33 (depends on 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 26 to 32, wherein the first ligand binding domain and second ligand binding domains are FKBP domains or FRB domains.

### Claim 34 (depends on 33)

The method of claim 33, wherein the FKBP domain is a mutant FKBP domain.

### Claim 35 (depends on 34)

The method of claim 34, wherein the mutant FKBP domain is the F36V FKBP mutant domain comprising the amino acid sequence GVQVETISPGDGRTFPKRGQTCVVH YTGMLEDGKKVDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDY AYGATGHPGIIPPHATLVFDVELLKLE (SEQ ID NO: 1) or MGVQVETISPGDGRTFPKR GQTCVVHYTGMLEDGKKVDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRA KLTISPDYAYGATGHPGIIPPHATLVFDVELLKLE (SEQ ID NO:2).

### Claim 36 (depends on 34)

The method of claim 34, wherein the mutant FKBP domain comprises a C22S, C22A, or C22V substitution.

### Claim 37 (depends on 33)

The method of claim 33, wherein the FRB domain comprises a C61S, C61A, or C61V substitution.

### Claim 38 (depends on 26, 27, 28, 29)

The method of any one of claims 26 to 29, wherein the first ligand and first ligand binding domain and/or the second ligand and second ligand binding domain are small interactive protein domain pairs.

### Claim 39 (depends on 38)

The method of claim 38, wherein the small interactive protein domain pairs are chosen from jun/fos, mad/max, myc/max, and NZ/CZ domains.

### Claim 40 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method according to any one of claims 26 to 39, wherein the reporter molecule is chosen from a luminescent protein, murine dihydrofolate reductase (DHFR), S. cerevisiae ubiquitin, β-lactamase, and Herpes simplex virus type 1 thymidine kinase.

### Claim 41 (depends on 40)

The method according to claim 40, wherein the reporter molecule is DHFR, and one of the first fragment of the reporter molecule and the second fragment of the reporter molecule comprises amino acids 1-105 of DHFR, and the other of the first fragment of the reporter molecule and second fragment of the reporter molecule comprises amino acids 106-186 of DHFR.

### Claim 42 (depends on 40)

The method according to claim 40, wherein the reporter molecule is S. cerevisiae ubiquitin, and one of the first fragment of the reporter molecule and the second fragment of the reporter molecule comprises amino acids 1-34 (MQIFVKTLTGKTITLEVESSDTIDNV KSKIQDKE; SEQ ID NO:3) of S. cerevisiae ubiquitin, and the other of the first fragment of the reporter molecule and second fragment of the reporter molecule comprises amino acids 35-76 (GIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG; SEQ ID NO:4) of S. cerevisiae ubiquitin.

### Claim 43 (depends on 40)

The method according to claim 40, wherein the reporter molecule is β-lactamase, and one of the first fragment of the reporter molecule and the second fragment of the reporter molecule comprises amino acids 25-197 of β-lactamase, and the other of the first fragment of the reporter molecule and second fragment of the reporter molecule comprises amino acids 198-286 of β-lactamase.

### Claim 44 (depends on 40)

The method according to claim 40, wherein the reporter molecule is Herpes simplex virus type 1 thymidine kinase, and one of the first fragment of the reporter molecule and the second fragment of the reporter molecule comprises amino acids 1-265 of Herpes simplex virus type 1 thymidine kinase, and the other of the first fragment of the reporter molecule and second fragment of the reporter molecule comprises amino acids 266-376 of Herpes simplex virus type 1 thymidine kinase.

### Claim 45 (depends on 40)

The method according to claim 40, wherein the luminescent protein is Gaussia luciferase, superfolder GFP (sfGFP), Renilla luciferase, or Nanoluc luciferase.

### Claim 46 (depends on 45)

The method according to claim 45, wherein the luminescent protein is Gaussia luciferase, and one of the first fragment of Gaussia luciferase and second fragment of Gaussia luciferase comprises MKPTENNEDFNIVAVASNFATTDLDADRGKLPGKKLPLEVLKE MEANARKAGCTRGCLICLSHIKCTPKMKKFIPGRCHTYEGDKESAQGGIG (SEQ ID NO:5), and the other of the first fragment of Gaussia luciferase and second fragment of Gaussia luciferase comprises EAIVDIPEIPGFKDLEPMEQFIAQVDLCVDCTTGCLKGLA NVQCSDLLKKWLPQRCATFASKIQGQVDKIKGAGGD (SEQ ID NO:6).

### Claim 47 (depends on 45)

The method according to claim 45, wherein the luminescent protein is sfGFP, and one of the first fragment of sfGFP and second fragment of sfGFP comprises MRKGEELFTG VVPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGKLPVPWPTLVTTLTYG VQCFARYPDHMKQHDFFKSAMPEGYVQERTISFKDDGTYKTRAEVKFEGDTLVNRI ELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQ (SEQ ID NO:7) or MSKGEELFTGV VPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGKLPVPWPTLVTTLTYGV QCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGTYKTRAEVKFEGDTLVNRIEL KGIDFKEDGNILGHKLEYNFNSHNVYITADKQ (SEQ ID NO:22), and the other of the first fragment of sfGFP and second fragment of sfGFP comprises KNGIKANFKIRHNVEDG SVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLSKDPNEKRDHMVLLEFVTAAGITH GMDELYK (SEQ ID NO:8).

### Claim 48 (depends on 45)

The method according to claim 45, wherein the luminescent protein is Renilla luciferase, and one of the first fragment of Renilla luciferase and second fragment of Renilla luciferase comprises MASKVYDPEQRKRMITGPQWWARCKQMNVLDSFINYYDSEKH AENAVIFLHGNAASSYLWRHVVPHIEPVARCIIPDLIGMGKSGKSGNGSYRLLDHYK YLTAWFELLNLPKKIIFVGHDWGACLAFHYSYEHQDKIKAIVHAESVVDVIESWDE WPDIEEDIALIKSEEGEKMVLENNFFVETMLPSKIMRKLEPEEFAAYLEPFKEKGEVR RPTLSWPREIPLVKGG (SEQ ID NO:9), and the other of the first fragment of Renilla luciferase and second fragment of Renilla luciferase comprises KPDVVQIVRNYNAYLRAS DDLPKMFIESDPGFFSNAIVEGAKKFPNTEFVKVKGLHFSQEDAPDEMGKYIKSFVER VLKNEQ (SEQ ID NO:10).

### Claim 49 (depends on 45)

The method according to claim 45, wherein the luminescent protein is Nanoluc luciferase, and one of the first fragment of Nanoluc luciferase and second fragment of Nanoluc luciferase comprises MFTLEDFVGDWEQTAAYNLDQVLEQGGVSSLLQNLAV SVTPIQRIVRSGENALKIDIHVIIPYEGLSADQMAQIEEVFKVVYPVDDHHFKVILPYG TLVIDGVTPNMLNYFGRPYEGIAVFDGKKITVTGTLWNGNKIIDERLITPDGSMLFRV TINS (SEQ ID NO:34), and the other of the first fragment of Nanoluc luciferase and second fragment of Nanoluc luciferase comprises VSGWRLFKKIS (SEQ ID NO:35) or VTGYRL FEEIL (SEQ ID NO:36).

### Claim 50

A method of determining surface glycan density of a cell, the method comprising the steps:
a) contacting the cell with an azide-modified sugar;
b) contacting the cell with a bifunctional compound, wherein the bifunctional compound comprises an azide reactive molecule that is chemically reactable with an azide group, and a small molecule ligand that binds to an FKBP domain or FRB domain, wherein the bifunctional compound associates with a first glycan molecule, and another bifunctional compound associates with a second glycan molecule;
c) contacting the cell with a first haplomer comprising an FKBP domain or FRB domain conjugated to a first fragment of a reporter molecule;
d) contacting the cell with a second haplomer comprising an FKBP domain or FRB domain conjugated to a second fragment of the reporter molecule;
whereby, upon association between the FKBP domain or FRB domain of the first haplomer and the small molecule ligand of the bifunctional molecule of a first glycan molecule and the association between the FKBP domain or FRB domain of the second haplomer and the small molecule ligand of the bifunctional molecule of a second glycan molecule in sufficient proximity to the first glycan molecule, and refolding of the first fragment of the reporter molecule with the second fragment of the reporter molecule, a functional reporter molecule is produced; and
e) detecting the amount of reporter molecule activity.

### Claim 51 (depends on 50)

The method according to claim 50, wherein the azide reactive molecule is dibenzocyclooctyne (DBCO), bicyclo[6.1.0]nonyne (BCN), methyltetrazine, or trans-cyclooctene (TCO).

### Claim 52 (depends on 50, 51)

The method according to claim 50 or claim 51, wherein the azide-modified sugar is azido-N-acetylmannosamine (AzNAM), azido-N-acetylglucosamine (AzGlcNAc), azido-N-acetylgalactosamine (AGalNAc), or azido-N-acetylneuraminic acid (AzNANA).

### Claim 53 (depends on 50, 51, 52)

The method according to any one of claims 50 to 52, wherein the azide-modified sugar is acetylated at 1, 2, 3, or 4 positions.

### Claim 54 (depends on 50, 51, 52, 53)

The method of any one of claims 50 to 53, wherein the small molecule ligand is an FKBP-binding compound.

### Claim 55 (depends on 54)

The method of claim 54, wherein the FKBP-binding compound is chosen from FKM-NHS, FKM-sulfo-NHS, FKM-PEG3-NHS, monovalent FKBP Ligand-2 (MFL2), FKM-PEG3-MTZ-NHS, and FKM-PEG3-TCO-NHS.

### Claim 56 (depends on 50, 51, 52, 53, 54, 55)

The method of any one of claims 50 to 55, wherein the FKBP domain is a mutant FKBP domain.

### Claim 57 (depends on 56)

The method of claim 56, wherein the mutant FKBP domain is the F36V FKBP mutant domain comprising the amino acid sequence GVQVETISPGDGRTFPKRGQTCVV HYTGMLEDGKKVDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPD YAYGATGHPGIIPPHATLVFDVELLKLE (SEQ ID NO: 1) or MGVQVETISPGDGRTFPK RGQTCVVHYTGMLEDGKKVDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQR AKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLE (SEQ ID NO:2).

### Claim 58 (depends on 56)

The method of claim 56, wherein the mutant FKBP domain comprises a C22S, C22A, or C22V substitution.

### Claim 59 (depends on 50, 51, 52, 53, 54, 55)

The method of any one of claims 50 to 55, wherein the FRB domain comprises a C61S, C61A, or C61V substitution.

### Claim 60 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 50 to 59, wherein the reporter molecule is chosen from a luminescent protein, murine dihydrofolate reductase (DHFR), S. cerevisiae ubiquitin, β-lactamase, and Herpes simplex virus type 1 thymidine kinase.

### Claim 61 (depends on 60)

The method according to claim 60, wherein the reporter molecule is DHFR, and one of the first fragment of the reporter molecule and the second fragment of the reporter molecule comprises amino acids 1-105 of DHFR, and the other of the first fragment of the reporter molecule and second fragment of the reporter molecule comprises amino acids 106-186 of DHFR.

### Claim 62 (depends on 60)

The method according to claim 60, wherein the reporter molecule is S. cerevisiae ubiquitin, and one of the first fragment of the reporter molecule and the second fragment of the reporter molecule comprises amino acids 1-34 (MQIFVKTLTGKTITLEVESSDTIDNV KSKIQDKE; SEQ ID NO:3) of S. cerevisiae ubiquitin, and the other of the first fragment of the reporter molecule and second fragment of the reporter molecule comprises amino acids 35-76 (GIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG; SEQ ID NO:4) of S. cerevisiae ubiquitin.

### Claim 63 (depends on 60)

The method according to claim 60, wherein the reporter molecule is β-lactamase, and one of the first fragment of the reporter molecule and the second fragment of the reporter molecule comprises amino acids 25-197 of β-lactamase, and the other of the first fragment of the reporter molecule and second fragment of the reporter molecule comprises amino acids 198-286 of β-lactamase.

### Claim 64 (depends on 60)

The method according to claim 60, wherein the reporter molecule is Herpes simplex virus type 1 thymidine kinase, and one of the first fragment of the reporter molecule and the second fragment of the reporter molecule comprises amino acids 1-265 of Herpes simplex virus type 1 thymidine kinase, and the other of the first fragment of the reporter molecule and second fragment of the reporter molecule comprises amino acids 266-376 of Herpes simplex virus type 1 thymidine kinase.

### Claim 65 (depends on 60)

The method according to claim 60, wherein the luminescent protein is Gaussia luciferase, superfolder GFP (sfGFP), Renilla luciferase, or Nanoluc luciferase.

### Claim 66 (depends on 65)

The method according to claim 65, wherein the luminescent protein is Gaussia luciferase, and one of the first fragment of Gaussia luciferase and second fragment of Gaussia luciferase comprises MKPTENNEDFNIVAVASNFATTDLDADRGKLPGKKLPLEVLKE MEANARKAGCTRGCLICLSHIKCTPKMKKFIPGRCHTYEGDKESAQGGIG (SEQ ID NO:5), and the other of the first fragment of Gaussia luciferase and second fragment of Gaussia luciferase comprises EAIVDIPEIPGFKDLEPMEQFIAQVDLCVDCTTGCLKGLA NVQCSDLLKKWLPQRCATFASKIQGQVDKIKGAGGD (SEQ ID NO:6).

### Claim 67 (depends on 65)

The method according to claim 65, wherein the luminescent protein is sfGFP, and one of the first fragment of sfGFP and second fragment of sfGFP comprises MRKGEELFTG VVPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGKLPVPWPTLVTTLTYG VQCFARYPDHMKQHDFFKSAMPEGYVQERTISFKDDGTYKTRAEVKFEGDTLVNRI ELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQ (SEQ ID NO:7) or MSKGEELFTGV VPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGKLPVPWPTLVTTLTYGV QCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGTYKTRAEVKFEGDTLVNRIEL KGIDFKEDGNILGHKLEYNFNSHNVYITADKQ (SEQ ID NO:22), and the other of the first fragment of sfGFP and second fragment of sfGFP comprises KNGIKANFKIRHNVEDG SVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLSKDPNEKRDHMVLLEFVTAAGITH GMDELYK (SEQ ID NO:8).

### Claim 68 (depends on 65)

The method according to claim 65, wherein the luminescent protein is Renilla luciferase, and one of the first fragment of Renilla luciferase and second fragment of Renilla luciferase comprises MASKVYDPEQRKRMITGPQWWARCKQMNVLDSFINYYDSEKH AENAVIFLHGNAASSYLWRHVVPHIEPVARCIIPDLIGMGKSGKSGNGSYRLLDHYK YLTAWFELLNLPKKIIFVGHDWGACLAFHYSYEHQDKIKAIVHAESVVDVIESWDE WPDIEEDIALIKSEEGEKMVLENNFFVETMLPSKIMRKLEPEEFAAYLEPFKEKGEVR RPTLSWPREIPLVKGG (SEQ ID NO:9), and the other of the first fragment of Renilla luciferase and second fragment of Renilla luciferase comprises KPDVVQIVRNYNAYLRAS DDLPKMFIESDPGFFSNAIVEGAKKFPNTEFVKVKGLHFSQEDAPDEMGKYIKSFVER VLKNEQ (SEQ ID NO:10).

### Claim 69 (depends on 65)

The method according to claim 65, wherein the luminescent protein is Nanoluc luciferase, and one of the first fragment of Nanoluc luciferase and second fragment of Nanoluc luciferase comprises MFTLEDFVGDWEQTAAYNLDQVLEQGGVSSLLQNLAV SVTPIQRIVRSGENALKIDIHVIIPYEGLSADQMAQIEEVFKVVYPVDDHHFKVILPYG TLVIDGVTPNMLNYFGRPYEGIAVFDGKKITVTGTLWNGNKIIDERLITPDGSMLFRV TINS (SEQ ID NO:34), and the other of the first fragment of Nanoluc luciferase and second fragment of Nanoluc luciferase comprises VSGWRLFKKIS (SEQ ID NO:35) or VTGYRL FEEIL (SEQ ID NO:36).

### Claim 70 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The method according to any one of claims 50 to 69, wherein the bifunctional compound comprises the formula:
wherein:
A is a small molecule ligand that binds to an FKBP domain or FRB domain;
B is a chemical linker chosen from an alkyl, an alkenyl, an amide, an ester, a thioester, a ketone, an ether, a thioether, a disulfide, an ethylene glycol unit, a cycloalkyl, a benzyl, a heterocyclic, a maleimidyl, a hydrazone, a urethane, an azole, an imine, a haloalkyl, or a carbamate, or any combination thereof; and
C is an azide reactive molecule chosen from a cyclooctyne, a norbornene, an oxanorbornadiene, a phosphine, a dialkyl phosphine, a trialkyl phosphine, a phosphinothiol, a phosphinophenol, a cyclooctene, a tetrazine, a tetrazole, or a quadricyclane.

### Claim 71 (depends on 70)

The method according to claim 70, wherein the FKBP domain is the FK506-FKBP domain or the mutant (F36V) FKBP domain.

### Claim 72 (depends on 70, 71)

The method according to claim 70 or claim 71, wherein the FKBP domain is the FK506-FKBP domain.

### Claim 73 (depends on 70, 71)

The method according to claim 70 or claim 71, wherein the FKBP domain is the mutant (F36V) FKBP domain.

### Claim 74 (depends on 70, 71)

The method according to claim 70 or claim 71, wherein the small molecule ligand is

### Claim 75 (depends on 70, 71, 72, 73, 74)

The method according to any one of claims 70 to 74, wherein the chemical linker is an alkyl or an ethylene glycol unit.

### Claim 76 (depends on 75)

The method according to claim 75, wherein the chemical linker is an alkyl.

### Claim 77 (depends on 76)

The method according to claim 76, wherein the chemical linker is a C2-C16alkyl.

### Claim 78 (depends on 77)

The method according to claim 77, wherein the chemical linker is a C4-C12alkyl or a C4-C16alkyl.

### Claim 79 (depends on 78)

The method according to claim 78, wherein the chemical linker is a C4-C10alkyl.

### Claim 80 (depends on 79)

The method according to claim 79, wherein the chemical linker is C4alkyl or C10alkyl.

### Claim 81 (depends on 75)

The method according to claim 75, wherein the chemical linker is an ethylene glycol unit.

### Claim 82 (depends on 81)

The method according to claim 81, wherein the chemical linker is a polyethylene glycol (PEG).

### Claim 83 (depends on 82)

The method according to claim 82, wherein the PEG is PEG2 to PEG16.

### Claim 84 (depends on 83)

The method according to claim 83, wherein the PEG is PEG2, PEG3, or PEG4.

### Claim 85 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84)

The method according to any one of claims 70 to 84, wherein the azide reactive molecule is chosen from a cyclooctyne, a cyclooctene, and a tetrazine.

### Claim 86 (depends on 85)

The method according to claim 85, wherein the cyclooctyne is dibenzocyclooctyne (DBCO), bicyclo[6.1.0]nonyne (BCN), monofluorinated cyclooctyne, difluorocyclooctyne, dimethoxyazacyclooctyne, dibenzoazacyclooctyne, biarylazacyclooctynone, 2,3,6,7-tetramethoxy-dibenzocyclooctyne, sulfonylated dibenzocyclooctyne, carboxymethylmonobenzocyclooctyne, or pyrrolocyclooctyne.

### Claim 87 (depends on 85)

The method according to claim 85, wherein the cyclooctene is trans-cyclooctene

### Claim 88 (depends on 85)

The method according to claim 85, wherein the tetrazine is methyltetrazine, diphenyltetrazine, 3,6-di-(2-pyridyl)-s-tetrazine, 3,6-diphenyl-s-tetrazine, 3-(5-aminopyridin-2-yl)-6-(pyridin-2-yl)-s-tetrazine, or N-benzoyl-3-(5-aminopyridin-2-yl)-6-(pyridin-2-yl)-s-tetrazine.

### Claim 89 (depends on 70)

The method according to claim 70, wherein:
the FKBP domain is the FK506-FKBP domain or the mutant (F36V) FKBP domain;
the chemical linker is an alkyl or an ethylene glycol unit; and
the azide reactive molecule is chosen from a cyclooctyne, a cyclooctene, and a tetrazine.

### Claim 90 (depends on 70)

The method according to claim 70, wherein:
the FKBP domain is the FK506-FKBP domain or the mutant (F36V) FKBP domain;
the chemical linker is a C2-C16alkyl, or a polyethylene glycol which is PEG2 to PEG16; and
the azide reactive molecule is DBCO, BCN, TCO, or methyltetrazine.

### Claim 91 (depends on 70)

The method according to claim 70, wherein:
the FKBP domain is the mutant (F36V), FKBP domain;
the chemical linker is a C4-C10alkyl or a polyethylene glycol which is PEG2, PEG3, or PEG4; and
the azide reactive molecule is DBCO, BCN, TCO, or methyltetrazine.

### Claim 92 (depends on 70)

The method according to claim 70, wherein:
the small molecule ligand is
the chemical linker is C4alkyl, C10alkyl, or PEG3; and
the azide reactive molecule is DBCO or BCN.

### Claim 93 (depends on 70)

The method according to claim 70, wherein the bifunctional compound comprises the formula:

### Claim 94 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

The method according to any one of claims 50 to 93, wherein the first haplomer and second haplomer are pre-incubated with excess bifunctional compound prior to their contacting the cells.
